Quick Takeaways
- Mark C. McKenna has 7 issuer positions tracked on this page.
- Estimated disclosed ownership value: $1,682,105.
- Recent insider filing activity is available below.
Insider Trading & Ownership of Mark C. McKenna
- Location
- Bridgewater, NJ
- Summary
- The estimated net worth of Mark C. McKenna is at least $1,682,105 dollars as of 22 Jan 2026. Mark C. McKenna is the Director of Apogee Therapeutics, Inc. and owns shares of Apogee Therapeutics, Inc. (APGE) stock worth about $997K. Mark C. McKenna is the Director of NewAmsterdam Pharma Co N.V. and owns shares of NewAmsterdam Pharma Co N.V. (NAMS) stock worth about $363.6K. Mark C. McKenna is the Former Director of Helix Acquisition Corp. II and owns shares of BridgeBio Oncology Therapeutics, Inc. (BBOT) stock worth about $321.5K.
- Signature
- /s/ Mark McKenna
- All Insider Reports
- All Insider Reports
Follow Filing Activity
Follow Mark C. McKenna and return when a new Insider Trading filing changes the record on this page.
This uses the existing product follow flow to surface future filing-backed changes without guessing what they mean. If you create an account from here, we will bring you back after verification.
What Changed
- Largest disclosed position: Apogee Therapeutics, Inc. ($997,000).
- Past-year value change for that position: .
Why This Matters
- This page translates Forms 3/4/5 into a quick ownership context before you inspect each transaction row.
- You can cross-check role, issuer, and filing chronology directly against the SEC source.
Source Evidence
Filed on Form 4
See Original Filing
Insider ownership context is sourced from SEC Forms 3, 4, and 5.
Ownership of Mark C. McKenna
| Symbol | Company | Relationship | Holdings Value | Past Year Net Change | Change % | Report Period |
|---|---|---|---|---|---|---|
| APGE | Apogee Therapeutics, Inc. | Director | $997,000 | 17 Jun 2025 | ||
| NAMS, NAMSW | NewAmsterdam Pharma Co N.V. | Director | $363,586 | 07 Jan 2026 | ||
| BBOT | Helix Acquisition Corp. II | Former Director | $321,519 | 11 Aug 2025 | ||
| HLXC | Helix Acquisition Corp. III | Director | 22 Jan 2026 | |||
| PCSC | Perceptive Capital Solutions Corp | Director | 11 Jun 2024 | |||
| RXDX | Prometheus Biosciences, Inc. | Chairman, President and CEO, Director | 16 Jun 2023 | |||
| SYRE | Spyre Therapeutics, Inc. | Director | 29 May 2025 |
Insider Transactions Reported by Mark C. McKenna:
| Sym | Company | Class | Transaction | % | Value $ | * Price $ | Shares | Shares After | Date | Ownership |
|---|
* An asterisk sign (*) next to the price indicates that the price is likely invalid.